Chronic CAD/Stable Ischemic Heart Disease
IMPACT OF CHRONIC CALCIUM CHANNEL BLOCKER THERAPY ON DEVELOPMENT OF NEW-ONSET DIABETES MELLITUS IN ASIAN POPULATION
- Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background
There have been several reports that calcium channel blocker (CCB) therapy is associated with a slightly higher incidence of new-onset diabetes mellitus (DM). It is still controversial whether the chronic CCB therapy is a risk factor of new onset DM, especially in Asian population.
Methods
We investigated the 4,231 patients (pts) who had HbA1C < 6.0% and fasting glucose < 100 mg/dL (CCB group=2,229 and control group=2,002). To adjust confounders, a propensity score matched analysis (PSM; CCB group=1,724 and control group=1,724) was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM (HbA1C > 6.5% or fasting glucose > 126 mg/dL). Also, Multivariable Cox-regression analysis adjusted by aforementioned variables was performed to determine the impact of CCB therapy on the incidence of new-onset DM.
Results
Mean follow-up duration was 908±558 days in all-pt group, and 905±559 days in propensity score matching group. Baseline characteristics was similar between the two groups except hypertension (58.6% vs. 55.1%, p=0.036) which was higher in the CCB group. In Kaplan-Meyer curve, there was no difference between the two groups (p=0.486, figure A). Also, in cox-regression analysis performed in all pts, CCB therapy was not associated with the increased incidence of primary end-point (figure B).
Conclusions
In our study, there was no clear association with CCB therapy and new-onset DM in a series of cardiovascular pts in Asian population.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
- Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background
There have been several reports that calcium channel blocker (CCB) therapy is associated with a slightly higher incidence of new-onset diabetes mellitus (DM). It is still controversial whether the chronic CCB therapy is a risk factor of new onset DM, especially in Asian population.
Methods
We investigated the 4,231 patients (pts) who had HbA1C < 6.0% and fasting glucose < 100 mg/dL (CCB group=2,229 and control group=2,002). To adjust confounders, a propensity score matched analysis (PSM; CCB group=1,724 and control group=1,724) was performed using the logistic regression model. The primary end-point was the cumulative incidence of new-onset DM (HbA1C > 6.5% or fasting glucose > 126 mg/dL). Also, Multivariable Cox-regression analysis adjusted by aforementioned variables was performed to determine the impact of CCB therapy on the incidence of new-onset DM.
Results
Mean follow-up duration was 908±558 days in all-pt group, and 905±559 days in propensity score matching group. Baseline characteristics was similar between the two groups except hypertension (58.6% vs. 55.1%, p=0.036) which was higher in the CCB group. In Kaplan-Meyer curve, there was no difference between the two groups (p=0.486, figure A). Also, in cox-regression analysis performed in all pts, CCB therapy was not associated with the increased incidence of primary end-point (figure B).
Conclusions
In our study, there was no clear association with CCB therapy and new-onset DM in a series of cardiovascular pts in Asian population.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
댓글 0